FADS2 and lung carcinoma: It has been found that FADS2 was abnormally expressed in liver cancer, glioblastoma, lung cancer and breast cancer, which may be an important biomarker of tumor metabolic reprogramming (Lane et al., 2003; Wang et al., 2018; Vriens et al., 2019; Li et al., 2020b).